{"id":56262,"date":"2026-02-04T21:04:51","date_gmt":"2026-02-04T13:04:51","guid":{"rendered":"https:\/\/flcube.com\/?p=56262"},"modified":"2026-02-04T21:04:53","modified_gmt":"2026-02-04T13:04:53","slug":"medtronic-to-acquire-cathworks-for-585m-expand-ai-based-ffrangio-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56262","title":{"rendered":"Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System"},"content":{"rendered":"\n

Medtronic Inc.<\/strong> (NYSE:\u202fMDT<\/a>) announced it will exercise its option to acquire Israel-based medical device company CathWorks<\/strong> for USD\u202f585\u202fmillion<\/strong>, aiming to transform the diagnosis and treatment of coronary artery disease (CAD). The transaction, expected to close in spring\u202f2026<\/strong>, follows a 2022 co-promotion partnership<\/strong> for CathWorks\u2019 FFRangio system<\/strong> in the United States, Europe, and Japan.<\/p>\n\n\n\n

Transaction Structure & Strategic Rationale<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Medtronic Inc. (NYSE:\u202fMDT)<\/td><\/tr>
Target<\/strong><\/td>CathWorks (Israel-headquartered)<\/td><\/tr>
Purchase Price<\/strong><\/td>USD\u202f585\u202fmillion<\/td><\/tr>
Expected Close<\/strong><\/td>Spring\u202f2026<\/td><\/tr>
Partnership History<\/strong><\/td>2022 co\u2011promotion agreement for FFRangio system<\/td><\/tr>
Strategic Goal<\/strong><\/td>Transform CAD diagnosis and treatment<\/td><\/tr>
Geographic Reach<\/strong><\/td>US, Europe, Japan (already commercially available)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Overview & Clinical Advantage<\/h2>\n\n\n\n

CathWorks\u2019 FFRangio system<\/strong> combines artificial intelligence (AI) and advanced computational science<\/strong> to provide comprehensive physiological assessment of the entire coronary tree directly from standard coronary angiograms (X\u2011rays). Clinical evidence indicates the system offers excellent diagnostic accuracy<\/strong> and favorable clinical outcomes compared to traditional wire\u2011based FFR measurements, reducing procedure time and improving patient safety.<\/p>\n\n\n\n

Market Impact & Commercial Outlook<\/h2>\n\n\n\n